Anzeige
Mehr »
Donnerstag, 04.09.2025 - Börsentäglich über 12.000 News
Set to Action: Q-Gold vor drastischer Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40UHG | ISIN: US7389201077 | Ticker-Symbol:
NASDAQ
04.09.25 | 21:54
0,545 US-Dollar
-7,14 % -0,042
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
ASPIRE BIOPHARMA HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
ASPIRE BIOPHARMA HOLDINGS INC 5-Tage-Chart

Aktuelle News zur ASPIRE BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiAspire Biopharma: Sublinguales Aspirin hemmt Blutgerinnung in Rekordzeit1
MiAspire Biopharma Holdings, Inc.: Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction230Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosingTxB2 is a biomarker indicating aspirin's effect on platelet aggregation...
► Artikel lesen
22.08.Aspire Biopharma schließt Kaufvertrag für Schuldverschreibungen über 9,7 Mio. US-Dollar ab4
22.08.Aspire Biopharma Holdings, Inc. - 8-K, Current Report2
18.08.Aspire Biopharma Holdings, Inc.: Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction451According to the NIH, Acute myocardial infarction (AMI) is a major cause of death, affecting nearly 3 million Americans each year and resulting in over a million deathsTrial demonstrates dramatically...
► Artikel lesen
ASPIRE BIOPHARMA Aktie jetzt für 0€ handeln
14.08.Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20159ESTERO, FL / ACCESS Newswire / August 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug and supplement delivery technology...
► Artikel lesen
13.08.Aspire Biopharma Holdings, Inc. - 10-Q, Quarterly Report1
13.08.Aspire Biopharma Holdings, Inc. - 10-Q/A, Quarterly Report2
13.08.Aspire Biopharma Holdings, Inc.: Aspire Biopharma Successfully Launches BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World290BUZZ BOMB is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential30,000 BUZZ BOMB sample...
► Artikel lesen
31.07.Aspire Biopharma startet Direktvertrieb für sublinguales Koffein-Supplement2
31.07.Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement334First sublingual pre-workout single-serving supplement that delivers 50mg of caffeine rapidly to the body, is now available to order via Aspire's new direct-to-consumer shopping experience ESTERO, FL...
► Artikel lesen
31.07.Aspire Biopharma names new executive chair4
31.07.Aspire Biopharma Holdings, Inc. Announces CEO Transition452Kraig Higginson, Current Chairman of the Board, Appointed Interim CEO ESTERO, FL / ACCESS Newswire / July 30, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer...
► Artikel lesen
30.07.Aspire Biopharma Holdings, Inc. - 8-K, Current Report1
25.07.Aspire Biopharma's BUZZ BOMB Shows Promising Initial Feedback3
22.07.Aspire Biopharma to launch sublingual pre-workout supplement at fitness expos3
22.07.Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World287Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market ESTERO, FL / ACCESS Newswire / July 22, 2025 / Aspire Biopharma Holdings...
► Artikel lesen
09.07.Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB, its New Sublingual Pre-Workout Supplement764Early positive consumer testimonials from initial Company product samplingSublingual nano technology delivers caffeine rapidly to the bloodstream, bringing its unique benefits to the pre-workout marketDeveloped...
► Artikel lesen
24.06.Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation285Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025 ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the...
► Artikel lesen
18.06.Aspire Biopharma Holdings, Inc. - 8-K, Current Report1
Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1